Analyst Ratings For Pfizer Inc. (NYSE:PFE)

Today, Credit Suisse Group set its price target on Pfizer Inc. (NYSE:PFE) to $45.00 per share.

There are 14 Hold Ratings, 7 Buy Ratings, 2 Sell Ratings, no Strong Buy Ratings on the stock.

The current consensus rating on Pfizer Inc. (NYSE:PFE) is Hold with a consensus target price of $43.80 per share, a potential 0.34% upside.

Some recent analyst ratings include

• 12/11/2018-Pfizer Inc. (NYSE:PFE) gets downgraded to Neutral by JPMorgan Chase & Co. with a price target of $46.00
• 11/27/2018-Pfizer Inc. (NYSE:PFE) had its Buy rating reiterated by Atlantic Securities with a $54.00 price target
• 11/1/2018-Pfizer Inc. (NYSE:PFE) gets downgraded to Market Perform by BMO Capital Markets with a price target of $46.00

• On 10/15/2018 Pfizer Inc, Major Shareholder, bought 55,556 with an average share price of $18.00 per share and the total transaction amounting to $1,000,008.00.
• On 8/13/2018 Laurie J Olson, Insider, sold 10,214 with an average share price of $41.00 per share and the total transaction amounting to $418,774.00.
• On 8/3/2018 Alexander R Mackenzie, Insider, sold 25,642 with an average share price of $39.51 per share and the total transaction amounting to $1,013,115.42.
• On 8/1/2018 Frank A Damelio, Insider, sold 150,484 with an average share price of $40.00 per share and the total transaction amounting to $6,019,360.00.
• On 8/1/2018 Kirsten Lund-Jurgensen, EVP, sold 20,942 with an average share price of $40.04 per share and the total transaction amounting to $838,517.68.
• On 8/1/2018 Loretta V Cangialosi, VP, sold 26,814 with an average share price of $40.16 per share and the total transaction amounting to $1,076,850.24.
• On 7/20/2018 Sally Susman, Insider, sold 40,381 with an average share price of $37.22 per share and the total transaction amounting to $1,502,980.82.

About Pfizer Inc. (NYSE:PFE)
Pfizer Inc. discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care. This segment offers products primarily under the Prevnar 13/Prevenar 13, Xeljanz, Eliquis, Lyrica, Enbrel, Ibrance, Xtandi, Advil, and Centrum brands. The EH segment offers products that would lose or have lost marketing patent protection; branded generic products; generic sterile injectable products; biosimilars; and anti-infectives. It provides products under the Lipitor, Premarin family, Norvasc, Lyrica, Celebrex, Viagra, Inflectra/Remsima, Pristiq, Zyvox, Vfend, Revatio, Inspra, Medrol, Sulperazon, Fragmin, Tygacil, Nivestim, and Retacrit brands. This segment also engages in the research and development, as well as contract manufacturing activities. The company serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. Pfizer Inc. has collaboration and/or co-promotion agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; Immunicum AB (publ); Immutep Limited; BioNTech AG; Neofluidics, LLC; Kite Pharma, Inc.; Leap Therapeutics, Inc.; Nektar Therapeutics; and Zenith Epigenetics Ltd., as well as development agreement with Antares Pharma, Inc. It also has a collaboration agreement with Aileron Therapeutics, Inc. The company was founded in 1849 and is headquartered in New York, New York.

Recent Trading Activity for Pfizer Inc. (NYSE:PFE)
Shares of Pfizer Inc. closed the previous trading session at 43.65 up +0.68 1.58% with shares trading hands.